Clinical Trial Update: A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating escalating doses of RO7297089 to assess safety and pharmacokinetics in patients with relapsed or refractory multiple myeloma; results h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• RO7297089 (RO7297089)

Snippet

Sponsor: Genentech, Inc. | Conditions: Refractory Multiple Myeloma, Relapsed Multiple Myeloma | Phase 1 | Status: COMPLETED | Results posted: 2024-07-03